Research on Lipodystrophy & Other Metabolic Complications

DO. SEE. HEAR. KNOW. Visit TheBody.com's 2008 World AIDS Day Center >>

BROWSE TOPICS IN HIV TREATMENT:

HIV Treatment: Home Page

Just Diagnosed

HIV Medications

First Steps to Treatment

HIV Drug Resistance

Switching or Stopping Treatment

Third Line/Rescue Treatment

Hepatitis C Coinfection

Women & Pregnancy

HIV Treatment for Children

Side Effects & Health Problems

Research & Experimental Drugs

HIV Treatment in the Developing World

2003 | 2002 | 2001 | 1997-2000

See also: Lipodystrophy Basics

2001

Metabolic Complications of HIV Disease (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
Select HIV Protease Inhibitors Alter Bone and Fat Metabolism In Vitro (December 16, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
Triglyceride Increase Can Predict Lipodystrophy in HIV Patients Under HAART (December 16, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
Associations Between Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Use and HIV-Associated Lipodystrophy Syndrome (HALS) in the Dagna-LipART Cohort Study (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
Rise in HDL Cholesterol Associated With Nevirapine Containing Antiretroviral Therapy in HIV-1 Infected Patients Is Sustained Over 48 Weeks of Treatment (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
Switching From PI-Based to NNRTI-Based Regimens: Clinical and Metabolic Outcomes (October 28, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
The Impact of First Line Therapies on Lipid Metabolism: The FRAMS Data (October 28, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
HIV-Positive Individuals and Fat Redistribution: Diet Modification May Be the Key (October 1, 2001)
To read PDF, click here
In STEP Ezine, from Seattle Treatment Education Project
Andractim for HAART-Associated Breast Enlargement (September 24, 2001)
From Canadian AIDS Treatment Information Exchange
Role of Diet in Lipodystrophy (September 5, 2001)
This report is from the Steven Grinspoon Group at Harvard.
From The National AIDS Education and Training Centers
Growth Hormone Used to Treat Humps and Excess Fat (August 21, 2001)
From Canadian AIDS Treatment Information Exchange
Carnitine for High Triglycerides (July 31, 2001)
From Canadian AIDS Treatment Information Exchange
Insulin Resistance in HIV Lipodystrophy Syndrome (July 2001)
In Body Positive, from Body Positive
Risk of Lipodystrophy in HIV-1-Infected Patients Treated with Protease Inhibitors: A Prospective Cohort Study (July 2001)
In Body Positive, from Body Positive
First-Ever Definition of HIV-Associated Lipodystrophy (Summer 2001)
In Women Alive Newsletter, from Women Alive
Lipodystrophy Syndrome: Uncertainties Remain (Summer/Autumn 2001)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
The Phenomena Formerly Known as Lipodystrophy (March 22, 2001)
Report from the 8th Conference on Retroviruses and Opportunistic Infections.
In STEP Ezine, from Seattle Treatment Education Project
Lipodystrophy Update: The Continuing Saga (March 2001)
To read PDF, click here
In Project Inform Perspective, from Project Inform
ACTG 5056: Metabolic Status and Cardiovascular Disease Risk for a Cohort of HIV-1-Infected Persons Durably Suppressed on an Indinavir-Containing Regimen (ACTG 372A) (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
An Open Randomized Study on the Replacement of HIV-1 Protease Inhibitors by Efavirenz in Chronically Suppressed HIV-1-Infected Patients with Lipodystrophy (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Does Race Protect an Asian Population from Developing Lipodystrophy in HIV-Infected Individuals on HAART? (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Long-Term Efficacy and Tolerance of Switching the Protease Inhibitor for Non-Nucleoside Reverse Transcriptase Inhibitors: A 52-Week, Multicenter, Prospective Study (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Metabolic and Clinical Evaluation of Lipodystrophy Syndrome (LD) in HIV-1-Infected Adults Receiving Initial HAART with or without a Protease Inhibitor (PI): 48-Week Data from the CNAF3007 Study (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Metabolic Complications of HIV-1 Disease (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Update: Treatment of Lipodystrophy (February 2001)
In HIV Newsline, from San Francisco General Hospital
Metabolic Abnormalities (2001)
From Forum for Collaborative HIV Research
The Buzz: Drug Holidays and Lipodystrophy: Ongoing Controversies and Research (January/February 2001)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.